---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-006087"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:36:59.307065+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Anebulo Pharma Q2 FY2024 net loss narrows to $2.7M; cash $6.6M; advancing selonabant

## Summary
- Net loss $2.7M ($0.11/sh) vs $3.8M ($0.15/sh) in Q2 FY2023; operating expenses $2.8M.
- Cash $6.6M at Dec 31, 2023; secured $10M credit facility from existing investors.
- Selonabant (ANEB-001) generic name adopted; IV formulation in development.
- Targeting Phase 3 study start in H1 2024; new CEO Richie Cunningham and board member Bimal Shah.

## SEC filing metadata
- accession: 0001493152-24-006087
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315224006087/0001493152-24-006087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315224006087/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-006087
- JSON: https://secwatch.observer/filing/0001493152-24-006087.json
- Plain text: https://secwatch.observer/filing/0001493152-24-006087.txt

## Key facts
- Earnings Releases
  Anebulo Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 m, EPS $(0.11) per share.
  - Period: the three months ended December 31, 2023
  - Net income: Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 m
  - EPS: $(0.11) per share
  - Result: reported results
  source text: Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315224006087/0001493152-24-006087-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.